

JC17 Rec'd PCT/PTO 09 JUN 2005

IN THE SPECIFICATION


Please substitute the following new paragraph after the "TITLE OF THE INVENTION" paragraph on page 1, lines 1-3:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a U.S. National Phase application under 35 U.S.C. §371 of PCT Application No. PCT/US2003/040040, filed December 15, 2003, which claims priority under 35 U.S.C. §119 from U.S. Provisional Application No. 60/435,436, filed December 19, 2002.

Please replace the paragraphs at page 61, lines 26-29 with the following amended paragraphs:

EXAMPLE 8




~~*N*-{[3-(4-Chlorophenyl)-2-(3-bromophenyl)-2-hydroxy-1(S)-methyl]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide (Diastereomer α)~~

N-{[3-(4-Chlorophenyl)-2-(3-cyanophenyl)-2-hydroxy-1(S)-methyl]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide (Diastereomer α)

Please replace the paragraphs at page 62 lines 12-17 with the following amended paragraphs:

EXAMPLE 9



~~*N*-{[3-(4-Chlorophenyl)-2-(3-bromophenyl)-2-hydroxy-1(R)-methyl]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide (Diastereomer α) *N*-{[3-(4-Chlorophenyl)-2-(3-cyanophenyl)-2-hydroxy-1(R)-methyl]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide (Diastereomer α)~~

The title compound was prepared following the procedure as described in Example 8 starting from D-alanine methyl ester. LC-MS: m/e 532 ($M + H$)⁺ (4.0 min).